Drugs / vaccinia-GM-CSF vaccine
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00002817 | Apr 1996 → ? | cutaneous melanoma | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vaccinia-GM-CSF vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002817 ↗ |
| Known as | rV-GM-CSF | “This is a dose-escalation study of intralesional recombinant vaccinia virus encoding the gene for sargramostim (GM-CSF) (rV-GM-CSF).” NCT00002817 ↗ |
| Modality | Vaccine | “Vaccine Therapy in Treating Patients With Metastatic Melanoma” NCT00002817 ↗ |
| Route | Other | “receive rV-GM-CSF intralesionally twice weekly for 5 weeks” NCT00002817 ↗ |